-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Looking back at November, fundraising in the pharmaceutical industry on a global scale was still frequent
.
According to incomplete statistics, a total of 10 pharmaceutical and biological companies worldwide went to IPO in November, with a total of nearly 1 billion U.
S.
dollars
.
Among them, including three local pharmaceutical companies, they are Linktop Bio, Clover Bio and Northland
.
Liantuo Biologics went public in the United States and raised US$325 million.
On October 28, 2021, Liantuo Biologics successfully listed on the Nasdaq IPO in the United States.
The issue price is US$16.
00, and US$325 million has been raised
.
At the same time, authorized underwriters can purchase additional 3.
046875 shares
.
According to data, Liantuo Bio is a clinical-stage biopharmaceutical company operating in China and the United States.
The company mainly promotes its diversified clinical drug candidate product pipeline through cooperation with highly innovative biopharmaceutical companies around the world, which may promote cardiovascular, New treatment standards for tumors, ophthalmology, inflammatory diseases and different indications of the respiratory system
.
The company has offices in Shanghai, China and Princeton, New Jersey, USA, focusing on the licensing, development and commercialization of therapeutic drugs in Greater China (including China, Hong Kong, Taiwan, and Macau) and other Asian markets
.
Clover Biologics landed on the Hong Kong Stock Exchange, raising HK$1.
87 billion.
On November 5, 2021, Clover Biologics was listed on the Hong Kong Stock Exchange with an issue price of HK$13.
38 and a net fundraising of HK$1.
87 billion
.
According to data, Clover Bio is a global clinical stage biotechnology company dedicated to developing new vaccines and biotherapeutic candidates for infectious diseases, cancer and autoimmune diseases, and solving global life-threatening diseases and public health threats
.
It is understood that before the IPO, Shamrock Bio has received investment blessings from many large institutions such as Hillhouse Capital, Temasek, and Aobo Capital
.
As of the completion of the global offering, Hillhouse Capital held 8.
53% and 6.
29% of the shares of Clover Biology through JNRY and AUT-XXI respectively, with a cumulative shareholding ratio of 14.
82%, ranking the third largest shareholder
.
Northland listed on the Beijing Stock Exchange On November 15th, the Beijing Stock Exchange opened the gong, and Northland, a subsidiary of Haikejin Group's Shangdi biological incubator incubator, was successfully listed on the Beijing Stock Exchange
.
According to data, Northland is an innovative biopharmaceutical company specializing in the research and development, production and sales of gene therapy drugs, recombinant protein drugs and ophthalmic drugs
.
Adhering to the tenet of "creating value and serving health" and adhering to the orientation of clinical demand, the company is mainly committed to the research and development and industrialization of new bioengineered drugs in the fields of cardiovascular disease, metabolic disease, rare disease and ophthalmological disease, and provides disease treatment Clinically accessible drugs that are safe, effective, and controllable in quality
.
It is worth mentioning that Northland recently issued an announcement that it plans to issue no more than 32 million shares to specific targets by way of bidding, accounting for 12.
44% of the current total share capital.
It is expected that the raised funds will not exceed 300 million yuan
.
According to the fixed increase draft, Northland's fixed increase financing will be used for drug research and development projects, bioengineering new drug industrialization projects and supplementary working capital, using the raised funds of 82.
170 million yuan, 189.
289 million yuan and 28.
541 million yuan respectively
.
Among them, the total investment of the bioengineering new drug industrialization project is 269,736,600 yuan, and the project has raised 80,447,600 yuan at the time of its initial public offering
.
.
According to incomplete statistics, a total of 10 pharmaceutical and biological companies worldwide went to IPO in November, with a total of nearly 1 billion U.
S.
dollars
.
Among them, including three local pharmaceutical companies, they are Linktop Bio, Clover Bio and Northland
.
Liantuo Biologics went public in the United States and raised US$325 million.
On October 28, 2021, Liantuo Biologics successfully listed on the Nasdaq IPO in the United States.
The issue price is US$16.
00, and US$325 million has been raised
.
At the same time, authorized underwriters can purchase additional 3.
046875 shares
.
According to data, Liantuo Bio is a clinical-stage biopharmaceutical company operating in China and the United States.
The company mainly promotes its diversified clinical drug candidate product pipeline through cooperation with highly innovative biopharmaceutical companies around the world, which may promote cardiovascular, New treatment standards for tumors, ophthalmology, inflammatory diseases and different indications of the respiratory system
.
The company has offices in Shanghai, China and Princeton, New Jersey, USA, focusing on the licensing, development and commercialization of therapeutic drugs in Greater China (including China, Hong Kong, Taiwan, and Macau) and other Asian markets
.
Clover Biologics landed on the Hong Kong Stock Exchange, raising HK$1.
87 billion.
On November 5, 2021, Clover Biologics was listed on the Hong Kong Stock Exchange with an issue price of HK$13.
38 and a net fundraising of HK$1.
87 billion
.
According to data, Clover Bio is a global clinical stage biotechnology company dedicated to developing new vaccines and biotherapeutic candidates for infectious diseases, cancer and autoimmune diseases, and solving global life-threatening diseases and public health threats
.
It is understood that before the IPO, Shamrock Bio has received investment blessings from many large institutions such as Hillhouse Capital, Temasek, and Aobo Capital
.
As of the completion of the global offering, Hillhouse Capital held 8.
53% and 6.
29% of the shares of Clover Biology through JNRY and AUT-XXI respectively, with a cumulative shareholding ratio of 14.
82%, ranking the third largest shareholder
.
Northland listed on the Beijing Stock Exchange On November 15th, the Beijing Stock Exchange opened the gong, and Northland, a subsidiary of Haikejin Group's Shangdi biological incubator incubator, was successfully listed on the Beijing Stock Exchange
.
According to data, Northland is an innovative biopharmaceutical company specializing in the research and development, production and sales of gene therapy drugs, recombinant protein drugs and ophthalmic drugs
.
Adhering to the tenet of "creating value and serving health" and adhering to the orientation of clinical demand, the company is mainly committed to the research and development and industrialization of new bioengineered drugs in the fields of cardiovascular disease, metabolic disease, rare disease and ophthalmological disease, and provides disease treatment Clinically accessible drugs that are safe, effective, and controllable in quality
.
It is worth mentioning that Northland recently issued an announcement that it plans to issue no more than 32 million shares to specific targets by way of bidding, accounting for 12.
44% of the current total share capital.
It is expected that the raised funds will not exceed 300 million yuan
.
According to the fixed increase draft, Northland's fixed increase financing will be used for drug research and development projects, bioengineering new drug industrialization projects and supplementary working capital, using the raised funds of 82.
170 million yuan, 189.
289 million yuan and 28.
541 million yuan respectively
.
Among them, the total investment of the bioengineering new drug industrialization project is 269,736,600 yuan, and the project has raised 80,447,600 yuan at the time of its initial public offering
.
